Human Papillomavirus Vaccination Coverage Among Girls Before 13 Years: A Birth Year Cohort Analysis of the National Immunization Survey-Teen, 2008-2013

Overview

Journal Clin Pediatr (Phila)

Publisher Sage Publications

Specialty Pediatrics

Date 2015 Nov 26

PMID 26603581

Citations 10

Authors

Jenny Jeyarajah

Laurie D Elam-Evans

Shannon Stokley

Philip J Smith

James A Singleton

Affiliations

Soon will be listed here.

Abstract

Routine human papillomavirus (HPV) vaccination is recommended at 11 or 12 years by the Advisory Committee on Immunization Practices. National Immunization Survey-Teen data were analyzed to evaluate, among girls, coverage with one or more doses of HPV vaccination, missed opportunities for HPV vaccination, and potential achievable coverage before 13 years. Results were stratified by birth year cohorts. HPV vaccination coverage before 13 years (≥1 HPV dose) increased from 28.4% for girls born in 1995 to 46.8% for girls born in 2000. Among girls born during 1999-2000 who had not received HPV vaccination before 13 years (57.2%), 80.1% had at least 1 missed opportunity to receive HPV vaccination before 13 years. Opportunities to vaccinate for HPV at age 11 to 12 years are missed. Strategies are needed to decrease these missed opportunities for HPV vaccination. This can be facilitated by the administration of all vaccines recommended for adolescents at the same visit.

Citing Articles

Human papillomavirus vaccination coverage among adolescent boys and girls in the United States: A birth year cohort analysis of the National Immunization Survey-Teen, 2016-2022.

Nyika P, Yankey D, Elam-Evans L, Meyer S, Pingali C, Stokley S Vaccine. 2024; 44():126560.

PMID: 39615345 PMC: 11694783. DOI: 10.1016/j.vaccine.2024.126560.

Varicella Vaccination Among US Adolescents: Coverage and Missed Opportunities, 2007-2014.

Leung J, Reagan-Steiner S, Lopez A, Jeyarajah J, Marin M J Public Health Manag Pract. 2018; 25(3):E19-E26.

PMID: 29889179 PMC: 6286230. DOI: 10.1097/PHH.0000000000000819.

Predictors of Human Papillomavirus Vaccine Follow-Through Among Privately Insured US Patients.

Spencer J, Brewer N, Trogdon J, Wheeler S, Dusetzina S Am J Public Health. 2018; 108(7):946-950.

PMID: 29771616 PMC: 5993378. DOI: 10.2105/AJPH.2018.304408.

Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007-2016.

Lewis R, Markowitz L Vaccine. 2018; 36(19):2567-2573.

PMID: 29650386 PMC: 5993427. DOI: 10.1016/j.vaccine.2018.03.083.

Operationalizing outcome measures of human papillomavirus vaccination among adolescents.

Odoh C, Sanderson M, Williams E, Hull P Public Health. 2018; 159:129-132.

PMID: 29609838 PMC: 5984163. DOI: 10.1016/j.puhe.2018.02.022.

References

Smith P, Chu S, Barker L . Children who have received no vaccines: who are they and where do they live?. Pediatrics. 2004; 114(1):187-95. DOI: 10.1542/peds.114.1.187. View

Holman D, Benard V, Roland K, Watson M, Liddon N, Stokley S . Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr. 2013; 168(1):76-82. PMC: 4538997. DOI: 10.1001/jamapediatrics.2013.2752. View

Laubereau B, Hermann M, Schmitt H, Weil J, von Kries R . Detection of delayed vaccinations: a new approach to visualize vaccine uptake. Epidemiol Infect. 2002; 128(2):185-92. PMC: 2869811. DOI: 10.1017/s0950268801006550. View

Perkins R, Clark J, Apte G, Vercruysse J, Sumner J, Wall-Haas C . Missed opportunities for HPV vaccination in adolescent girls: a qualitative study. Pediatrics. 2014; 134(3):e666-74. DOI: 10.1542/peds.2014-0442. View

Rand C, Shone L, Albertin C, Auinger P, Klein J, Szilagyi P . National health care visit patterns of adolescents: implications for delivery of new adolescent vaccines. Arch Pediatr Adolesc Med. 2007; 161(3):252-9. DOI: 10.1001/archpedi.161.3.252. View

. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011; 60(50):1705-8. View

Zhao Z, Murphy T, Jacques-Carroll L . Progress in newborn hepatitis B vaccination by birth year cohorts-1998-2007, USA. Vaccine. 2011; 30(1):14-20. DOI: 10.1016/j.vaccine.2011.10.076. View

. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb Mortal Wkly Rep. 2008; 57(40):1100-3. View

Schiffman M, Castle P . Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003; 127(8):930-4. DOI: 10.5858/2003-127-930-HPEAPH. View

10.

Vadaparampil S, Kahn J, Salmon D, Lee J, Quinn G, Roetzheim R . Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine. 2011; 29(47):8634-41. PMC: 3200426. DOI: 10.1016/j.vaccine.2011.09.006. View

11.

Stokley S, Cohn A, Jain N, McCauley M . Compliance with recommendations and opportunities for vaccination at ages 11 to 12 years: evaluation of the 2009 national immunization survey-teen. Arch Pediatr Adolesc Med. 2011; 165(9):813-8. DOI: 10.1001/archpediatrics.2011.138. View

12.

Petrosky E, Bocchini Jr J, Hariri S, Chesson H, Curtis C, Saraiya M . Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015; 64(11):300-4. PMC: 4584883. View

13.

Trottier H, Burchell A . Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics. 2009; 12(5-6):291-307. DOI: 10.1159/000214920. View

14.

Broder K, Cohn A, Schwartz B, Klein J, Fisher M, Fishbein D . Adolescent immunizations and other clinical preventive services: a needle and a hook?. Pediatrics. 2008; 121 Suppl 1:S25-34. DOI: 10.1542/peds.2007-1115D. View

15.

Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J . Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. MMWR Morb Mortal Wkly Rep. 2014; 63(29):620-4. PMC: 5779422. View

16.

Markowitz L, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E . Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2):1-24. View

17.

Dorell C, Yankey D, Jeyarajah J, Stokley S, Fisher A, Markowitz L . Delay and refusal of human papillomavirus vaccine for girls, national immunization survey-teen, 2010. Clin Pediatr (Phila). 2014; 53(3):261-9. PMC: 6167750. DOI: 10.1177/0009922813520070. View

18.

Tissot A, Zimet G, Rosenthal S, Bernstein D, Wetzel C, Kahn J . Effective strategies for HPV vaccine delivery: the views of pediatricians. J Adolesc Health. 2007; 41(2):119-25. PMC: 1989117. DOI: 10.1016/j.jadohealth.2007.05.007. View

19.

. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010; 59(20):626-9. View

20.

Elam-Evans L, Yankey D, Jeyarajah J, Singleton J, Curtis R, MacNeil J . National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2013. MMWR Morb Mortal Wkly Rep. 2014; 63(29):625-33. PMC: 5779424. View